Anti-CCAR1 autoantibodies are specific for anti-TIF1γ-positive dermatomyositis and decrease cancer risk relative to the general population.

David FiorentinoChristopher A MecoliTak IgusaJemima Albayda Julie J Paik Eleni TiniakouBrittany AdlerAndrew Lee MammenAmi A ShahAntony RosenLisa Christopher-Stine Livia A Casciola-Rosen

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2023)

Anti-CCAR1 autoantibodies are specific for anti-TIF1-γ-positive dermatomyositis. Their presence in anti-TIF1-γ-positive patients attenuates the risk of cancer to a level comparable to that seen in the general population.

Keyphrases

end stage renal disease
systemic lupus erythematosus
newly diagnosed
chronic kidney disease
ejection fraction
disease activity
rheumatoid arthritis
peritoneal dialysis
young adults
papillary thyroid
systemic sclerosis
patient reported outcomes
squamous cell
childhood cancer